CEO辞职引发业绩预期腰斩 美银下调联合健康(UNH.US)评级至“中性”

Core Viewpoint - Bank of America downgraded the stock rating of UnitedHealth Group (UNH.US) due to management turmoil, leading to a significant revision of 2025 earnings expectations [1] Company Summary - UnitedHealth Group's stock experienced an 18% drop, marking its largest single-day decline since 2011 [1] - The sudden resignation of CEO Andrew Witty and the withdrawal of the 2025 financial guidance caused market turbulence [1] - Analyst Joanna Gajuk downgraded the rating from "Buy" to "Neutral" and reduced the target price from $560 to $350, a decrease of 37.5% [1] - Expected earnings per share for 2025 are projected to decline by 10%-20%, with potential reductions of 21%-29% compared to initial long-term targets [1][2] Industry Summary - The decision to withdraw earnings guidance reflects two major concerns: management's lack of judgment on the sustainability of rising medical costs and the need for the new CEO to have sufficient time to develop a strategic plan [2] - UnitedHealth is planning to establish a new bidding strategy in the coming months, aiming to restore a 3%-5% operating margin in the Medicare Advantage segment, potentially at the cost of member growth stagnation or loss [2] - Competitor Humana (HUM.US) is facing challenges primarily due to internal governance issues, and the CEO's abrupt departure at UnitedHealth signals internal management disorder rather than systemic risks in the health management industry [2] - The management upheaval highlights the vulnerability of health insurance giants under medical inflation pressure and prompts a reevaluation of valuation frameworks in the healthcare sector as the 2025 Medicare bidding season approaches [2]